GPP
RLMD icon

Great Point Partners’s Relmada Therapeutics RLMD Stock Holding History

Great Point Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.83M Hold
842,106
– – 1.1% 26
2026
Q1 		$5.86M Buy
+842,106
New +$3.98M 1.35% 28
2022
Q4 		– Sell
-510,000
Closed -$18.9M – 52
2022
Q3 		$18.9M Sell
510,000
-190,000
-27% -$5.26M 4.55% 9
2022
Q2 		$13.3M Sell
700,000
-90,000
-11% -$1.96M 3.19% 13
2022
Q1 		$21.3M Buy
790,000
+72,680
+10% +$1.5M 5.15% 11
2021
Q4 		$16.2M Buy
+717,320
New +$16M 3.59% 9

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Great Point Partners's RLMD Position: Q2 2026 in Review

Great Point Partners held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 842,106 shares worth $5.83M. The position accounts for 1.1% of the portfolio, ranked #26.

Great Point Partners first reported a position in RLMD in Q4 2021 and has held it in 6 quarters since. The position peaked at $21.3M in Q1 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Great Point Partners held 842,106 shares of Relmada Therapeutics worth $5.83M as of Q2 2026.
  • Great Point Partners left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up 1.1% of Great Point Partners's portfolio in Q2 2026, its #26 holding.
  • Great Point Partners first reported a position in Relmada Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • Great Point Partners's Relmada Therapeutics position peaked at $21.3M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.